AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11130294 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human GH (hGH) at a dose of 0.125 U.kg‐1.wk‐1 for four weeks and 0.25 U.kg‐1.wk‐1 thereafter
Number of subjects: 9
Study 11130294 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human GH (hGH)
Number of subjects: 9
Study 8656490 — intervention group
Group type: EXPERIMENTAL
Intervention: Interlocking nail
Number of subjects: 116
Study 8656490 — intervention group
Group type: COMPARATOR
Intervention: Ender nail
Number of subjects: 116
Study 1626114 — intervention group
Group type: EXPERIMENTAL
Intervention: Methacholine (Mch) test
Number of subjects: 24
Study 1626114 — intervention group
Group type: COMPARATOR
Intervention: Nebulized ultrasonic distilled water (NUDW) test
Number of subjects: 24
Study 6384817 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 X 10(6) IU of natural alpha interferon daily for 6 months
Number of subjects: 24
Study 6384817 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 24
Study 30130145 — intervention group
Group type: EXPERIMENTAL
Intervention: Nothophaeocryptopus gaeumannii population in New Zealand
Number of subjects: 2085
Study 30130145 — intervention group
Group type: EXPERIMENTAL
Intervention: Nothophaeocryptopus gaeumannii populations in North and South Islands
Number of subjects: 2085
Study 30130145 — intervention group
Group type: EXPERIMENTAL
Intervention: Nothophaeocryptopus gaeumannii isolates
Number of subjects: 2085
Study 30130145 — intervention group
Group type: EXPERIMENTAL
Intervention: Nothophaeocryptopus gaeumannii introduction
Number of subjects: 2085
Study 30454052 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluralaner plus moxidectin (Bravecto® Plus)
Number of subjects: 707
Study 30454052 — intervention group
Group type: COMPARATOR
Intervention: Fipronil (Frontline®)
Number of subjects: 707
Study 26670987 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression Stockings (CS)
Number of subjects: 19
Study 26670987 — intervention group
Group type: COMPARATOR
Intervention: Regular Socks
Number of subjects: 19
Study 25040192 — intervention group
Group type: COMPARATOR
Intervention: Sofosbuvir + ribavirin (POSITRON)
Number of subjects: 994
Study 25040192 — intervention group
Group type: COMPARATOR
Intervention: Sofosbuvir + ribavirin (FUSION)
Number of subjects: 994
Study 25040192 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir + ribavirin (FISSION)
Number of subjects: 994
Study 25040192 — intervention group
Group type: COMPARATOR
Intervention: Sofosbuvir + ribavirin + interferon (NEUTRINO)
Number of subjects: 994
Study 25040192 — intervention group
Group type: COMPARATOR
Intervention: Pegylated interferon + ribavirin (FISSION)
Number of subjects: 994
Study 22205314 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine supplementation (various doses from 0 to 2000 μg/d)
Number of subjects: 256
Study 22205314 — intervention group
Group type: EXPERIMENTAL
Intervention: High-iodine intervention groups (1500-2000 μg)
Number of subjects: 256
Study 22205314 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 μg I supplementation
Number of subjects: 256
Study 22205314 — intervention group
Group type: EXPERIMENTAL
Intervention: 500-2000 μg I supplementation
Number of subjects: 256
Study 22205314 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 256
Study 20150398 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg per day + interferon beta-1a
Number of subjects: 45
Study 20150398 — intervention group
Group type: COMPARATOR
Intervention: Interferon beta-1a alone
Number of subjects: 45
Study 17295573 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine + Cognitive-Behavioral Therapy (CBT)
Number of subjects: 384
Study 17295573 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine only (Medication-only group)
Number of subjects: 384
Study 15728784 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) with prednisolone
Number of subjects: 64
Study 15728784 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide followed by azathioprine (CTX-AZA) with prednisolone
Number of subjects: 64
Study 12353189 — intervention group
Group type: EXPERIMENTAL
Intervention: Valacyclovir 1000 mg twice daily for 1 day
Number of subjects: 308
Study 12353189 — intervention group
Group type: EXPERIMENTAL
Intervention: Valacyclovir 500 mg twice daily for 3 days
Number of subjects: 308
Study 12353189 — intervention group
Group type: EXPERIMENTAL
Intervention: Valacyclovir (both regimens)
Number of subjects: 308
Study 10786413 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based refusal skills training
Number of subjects: 188
Study 10786413 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 188
Study 7774537 — intervention group
Group type: EXPERIMENTAL
Intervention: Pakistani women
Number of subjects: 58
Study 1574336 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg/day)
Number of subjects: 10
Study 1574336 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (150 mg/day)
Number of subjects: 10
Study 1574336 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 3893703 — intervention group
Group type: EXPERIMENTAL
Intervention: clebopride (0.5 mg TID)
Number of subjects: 76
Study 3893703 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 76
Study 30948606 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital at home (HAH) care
Number of subjects: 89
Study 30948606 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitators of HAH
Number of subjects: 89
Study 30948606 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers to HAH
Number of subjects: 89
Study 30948606 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurses' perspective on HAH
Number of subjects: 89
Study 30948606 — intervention group
Group type: EXPERIMENTAL
Intervention: Operational concerns regarding HAH
Number of subjects: 89
Study 29108456 — intervention group
Group type: EXPERIMENTAL
Intervention: Recognition memory task
Number of subjects: 0
Study 29108456 — intervention group
Group type: EXPERIMENTAL
Intervention: Probability manipulation
Number of subjects: 0
Study 29108456 — intervention group
Group type: EXPERIMENTAL
Intervention: Response payoff manipulation
Number of subjects: 0
Study 26715086 — intervention group
Group type: EXPERIMENTAL
Intervention: SOSTA-FRA (12 sessions)
Number of subjects: 209
Study 26715086 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 209
Study 24899339 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group with control measures (mixer lid, divider oil, focused training)
Number of subjects: 30
Study 24899339 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 24899339 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of mixer lid
Number of subjects: 30
Study 24899339 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of divider oil
Number of subjects: 30
Study 24899339 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused training
Number of subjects: 30
Study 24899339 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of all control measures
Number of subjects: 30
Study 22571813 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine-repeat CT group (n = 89)
Number of subjects: 171
Study 22571813 — intervention group
Group type: COMPARATOR
Intervention: Non-routine-repeat CT group (n = 82)
Number of subjects: 171
Study 22571813 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine-repeat CT group (mild TBI)
Number of subjects: 171
Study 22571813 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine-repeat CT group (moderate and severe TBI)
Number of subjects: 171
Study 19641919 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous temozolomide (150 mg/m2 as a 90-min infusion)
Number of subjects: 0
Study 19641919 — intervention group
Group type: COMPARATOR
Intervention: Oral temozolomide (200 mg/m2 on days 1, 2, and 5; 150 mg/m2 on days 3 and 4)
Number of subjects: 0
Study 18593390 — intervention group
Group type: EXPERIMENTAL
Intervention: NPWT-instillation
Number of subjects: 15
Study 18593390 — intervention group
Group type: COMPARATOR
Intervention: Standard moist wound-care therapy
Number of subjects: 15
Study 16821205 — intervention group
Group type: COMPARATOR
Intervention: Group B (menopausal women)
Number of subjects: 15
Study 16821205 — intervention group
Group type: COMPARATOR
Intervention: Group C (normally menstruating women)
Number of subjects: 15
Study 16821205 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (premature ovarian failure)
Number of subjects: 15
Study 12568976 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg/die valerian extract LI 156 (Sedonium)
Number of subjects: 202
Study 12568976 — intervention group
Group type: COMPARATOR
Intervention: 10 mg/die oxazepam
Number of subjects: 202
Study 9780763 — intervention group
Group type: EXPERIMENTAL
Intervention: 3‐in‐1 block with 40 mL of 1.5% mepivacaine (T group, n = 20)
Number of subjects: 40
Study 9780763 — intervention group
Group type: COMPARATOR
Intervention: Subarachnoid puncture with 3 mL of 2% lidocaine (S group, n = 20)
Number of subjects: 40
Study 7932518 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (20-40 mg daily)
Number of subjects: 110
Study 7932518 — intervention group
Group type: COMPARATOR
Intervention: Diltiazem SR (120-180 mg twice daily)
Number of subjects: 110
Study 3219879 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination inhaler of salbutamol (800 micrograms) and beclomethasone dipropionate (400 micrograms)
Number of subjects: 39
Study 3219879 — intervention group
Group type: COMPARATOR
Intervention: Separate inhalers of salbutamol (800 micrograms) and beclomethasone dipropionate (400 micrograms)
Number of subjects: 39
Study 29330194 — intervention group
Group type: EXPERIMENTAL
Intervention: Telotristat ethyl 250 mg tid
Number of subjects: 76
Study 29330194 — intervention group
Group type: EXPERIMENTAL
Intervention: Telotristat ethyl 500 mg tid
Number of subjects: 76
Study 29330194 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 26756383 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal injection of a dexamethasone implant (IVI‐DEX) after switching from bevacizumab (AD group)
Number of subjects: 48
Study 26756383 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab followed by intravitreal injection of a dexamethasone implant (DA group)
Number of subjects: 48
Study 25316130 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirfenidone therapy (600 mg/day for 8 weeks) with add-on rikkunshi-to from week 4
Number of subjects: 17
Study 25316130 — intervention group
Group type: EXPERIMENTAL
Intervention: Rikkunshi-to
Number of subjects: 17
Study 25316130 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirfenidone therapy (1200 mg/day)
Number of subjects: 17
Study 25316130 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 17
Study 25316130 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of plasma levels of acyl-ghrelin and des-acyl-ghrelin, serum KL-6 and surfactant protein-D, and pulmonary function tests
Number of subjects: 17
Study 23508526 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal system (≤ 16 mg/24 h)
Number of subjects: 381
Study 20117910 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine infiltration (Gr B)
Number of subjects: 0
Study 20117910 — intervention group
Group type: COMPARATOR
Intervention: Placebo infiltration (Gr P)
Number of subjects: 0
Study 18259028 — intervention group
Group type: EXPERIMENTAL
Intervention: 17beta‐estradiol (1 mg/d)
Number of subjects: 14
Study 18259028 — intervention group
Group type: COMPARATOR
Intervention: Enalaprilat (0.33 microg/min/100 mL forearm volume)
Number of subjects: 14
Study 16736149 — intervention group
Group type: EXPERIMENTAL
Intervention: Navigation (using Stryker, Orthopilot, and Navitrack systems)
Number of subjects: 0
Study 16736149 — intervention group
Group type: COMPARATOR
Intervention: Manual instrumentation
Number of subjects: 0
Study 14603216 — intervention group
Group type: EXPERIMENTAL
Intervention: Reversed saphenous vein (SV) graft
Number of subjects: 51
Study 14603216 — intervention group
Group type: COMPARATOR
Intervention: Polytetrafluoroethylene (PTFE) graft
Number of subjects: 51
Study 10958090 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral spinal anesthesia with 8 mg hyperbaric bupivacaine 0.5%
Number of subjects: 100
Study 10958090 — intervention group
Group type: COMPARATOR
Intervention: Bilateral spinal anesthesia with 8 mg hyperbaric bupivacaine 0.5%
Number of subjects: 100
Study 10958090 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral spinal anesthesia
Number of subjects: 100
Study 10958090 — intervention group
Group type: COMPARATOR
Intervention: Bilateral spinal anesthesia
Number of subjects: 100
Study 8881622 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforced laryngeal mask airway (LMA)
Number of subjects: 100
Study 8881622 — intervention group
Group type: COMPARATOR
Intervention: Nasotracheal tube
Number of subjects: 100
Study 8449845 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative antibiotic prophylaxis (cephalosporins used in 86% of cases)
Number of subjects: 2587
Study 8449845 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis (control group)
Number of subjects: 2587
Study 3780688 — intervention group
Group type: COMPARATOR
Intervention: 5.0% enflurane in 50% N2O (group E50)
Number of subjects: 30
Study 3780688 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.2% enflurane in 70% N2O (group E70)
Number of subjects: 30
Study 31380688 — intervention group
Group type: EXPERIMENTAL
Intervention: OurRelationship program
Number of subjects: 213
Study 31380688 — intervention group
Group type: COMPARATOR
Intervention: 2-month waitlist condition
Number of subjects: 213
Study 29237204 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive intravenous hydration with lactated Ringer's solution (3 mL/kg/h during ERCP, a 20-mL/kg bolus, and 3 mL/kg/h for 8 hours after ERCP)
Number of subjects: 395
Study 29237204 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive intravenous hydration with normal saline solution (3 mL/kg/h during ERCP, a 20-mL/kg bolus, and 3 mL/kg/h for 8 hours after ERCP)
Number of subjects: 395
Study 29237204 — intervention group
Group type: COMPARATOR
Intervention: Standard intravenous hydration with lactated Ringer's solution (1.5 mL/kg/h during and for 8 hours after ERCP)
Number of subjects: 395
Study 28404092 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide 25 mg
Number of subjects: 426
Study 28404092 — intervention group
Group type: COMPARATOR
Intervention: Tenofovir disoproxil fumarate 300 mg
Number of subjects: 426
Study 23864247 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of bacterial biofilms (study group)
Number of subjects: 80
Study 23864247 — intervention group
Group type: COMPARATOR
Intervention: No presence of bacterial biofilms (control group)
Number of subjects: 80
Study 22281609 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg/kg emodin
Number of subjects: 1200
Study 22281609 — intervention group
Group type: EXPERIMENTAL
Intervention: 700 mg/kg vitamin C (Vc)
Number of subjects: 1200
Study 22281609 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg/kg emodin + 700 mg/kg vitamin C (Vc)
Number of subjects: 1200
Study 22281609 — intervention group
Group type: COMPARATOR
Intervention: Control group (basal diet with 50.3 mg/kg Vc)
Number of subjects: 1200
Study 20551583 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rehydration solution (ORS)
Number of subjects: 153
Study 20551583 — intervention group
Group type: COMPARATOR
Intervention: Free-choice of their favorite drink (FAD)
Number of subjects: 153
Study 18514746 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine (0.3 mg subcutaneous)
Number of subjects: 0
Study 18514746 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil (5 mg oral)
Number of subjects: 0
Study 18514746 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine with Donepezil
Number of subjects: 0
Study 18514746 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16422894 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram treatment for 8 weeks
Number of subjects: 30
Study 16422894 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 30
Study 12734150 — intervention group
Group type: EXPERIMENTAL
Intervention: CSL 1.5 mL.kg(‐1) per hour fasting duration
Number of subjects: 120
Study 12734150 — intervention group
Group type: EXPERIMENTAL
Intervention: CSL 1.5 mL.kg(‐1) per hour fasting duration with 0.5 g.kg(‐1) dextrose added
Number of subjects: 120
Study 12734150 — intervention group
Group type: COMPARATOR
Intervention: No iv fluid (control)
Number of subjects: 120
Study 12734150 — intervention group
Group type: EXPERIMENTAL
Intervention: CSL/dextrose vs control
Number of subjects: 120
Study 12734150 — intervention group
Group type: EXPERIMENTAL
Intervention: CSL/dextrose vs CSL and control
Number of subjects: 120
Study 10599721 — intervention group
Group type: COMPARATOR
Intervention: recombinant human GH (rhGH) 6.25 microg/kg LBM for 1 month, 12.5 microg/kg LBM thereafter
Number of subjects: 28
Study 10599721 — intervention group
Group type: COMPARATOR
Intervention: recombinant human GH (rhGH)
Number of subjects: 28
Study 7579030 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (60 mg)
Number of subjects: 10
Study 1936347 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic therapy
Number of subjects: 0
Study 1936347 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6999349 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 203
Study 6999349 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 203
Study 30371854 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced awakenings (FA) -200 min sleep time
Number of subjects: 79
Study 30371854 — intervention group
Group type: COMPARATOR
Intervention: Undisturbed sleep (US)
Number of subjects: 79
Study 26773557 — intervention group
Group type: EXPERIMENTAL
Intervention: IDegAspSimple titration algorithm
Number of subjects: 0
Study 26773557 — intervention group
Group type: COMPARATOR
Intervention: IDegAspStepwise titration algorithm
Number of subjects: 0
Study 26773557 — intervention group
Group type: COMPARATOR
Intervention: IDegAspStepwise
Number of subjects: 0
Study 26773557 — intervention group
Group type: EXPERIMENTAL
Intervention: IDegAspSimple
Number of subjects: 0
Study 26773557 — intervention group
Group type: EXPERIMENTAL
Intervention: IDegAspSimple and IDegAspStepwise
Number of subjects: 0
Study 26093487 — intervention group
Group type: EXPERIMENTAL
Intervention: Effect-site remifentanil concentration before bolus administration
Number of subjects: 23
Study 26093487 — intervention group
Group type: EXPERIMENTAL
Intervention: Effect-site remifentanil concentration at spontaneous vaginal delivery
Number of subjects: 23
Study 26093487 — intervention group
Group type: EXPERIMENTAL
Intervention: Effect-site remifentanil concentration during the third quarter
Number of subjects: 23
Study 23216875 — intervention group
Group type: EXPERIMENTAL
Intervention: Low effect-site concentration of propofol (1.5-2.5 μg/mL)
Number of subjects: 121
Study 23216875 — intervention group
Group type: COMPARATOR
Intervention: High effect-site concentration of propofol (3.0-4.0 μg/mL)
Number of subjects: 121
Study 21239082 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonographically guided needle aspiration
Number of subjects: 101
Study 21239082 — intervention group
Group type: COMPARATOR
Intervention: Incision and drainage
Number of subjects: 101
Study 21239082 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonographically guided needle aspiration in patients with CA‐MRSA
Number of subjects: 101
Study 21239082 — intervention group
Group type: EXPERIMENTAL
Intervention: Incision and drainage in patients with CA‐MRSA
Number of subjects: 101
Study 21239082 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonographically guided needle aspiration versus incision and drainage in patients with CA‐MRSA
Number of subjects: 101
Study 21239082 — intervention group
Group type: COMPARATOR
Intervention: Incision and drainage versus ultrasonographically guided needle aspiration
Number of subjects: 101
Study 21239082 — intervention group
Group type: EXPERIMENTAL
Intervention: Incision and drainage in patients without CA‐MRSA
Number of subjects: 101
Study 18680213 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 108
Study 18680213 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 108
Study 18680213 — intervention group
Group type: COMPARATOR
Intervention: Conventional medications
Number of subjects: 108
Study 16601984 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-inflammatory drug for 2 weeks
Number of subjects: 38
Study 16601984 — intervention group
Group type: COMPARATOR
Intervention: No anti-inflammatory drug (control)
Number of subjects: 38
Study 14562669 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta blocker therapy
Number of subjects: 2894
Study 14562669 — intervention group
Group type: COMPARATOR
Intervention: No beta blocker therapy (Control)
Number of subjects: 2894
Study 11033985 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium Chain Triglycerides (MCT)
Number of subjects: 12
Study 8782139 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise program (aerobic, flexibility, and strengthening elements), 3 times per week for 6 weeks, 1 hour each session.
Number of subjects: 60
Study 8782139 — intervention group
Group type: COMPARATOR
Intervention: Relaxation group, 3 times per week for 6 weeks, 1 hour each session.
Number of subjects: 60
Study 1476277 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous i.v. infusion of 1 mg.kg‐1 of morphine (group 2)
Number of subjects: 30
Study 1476277 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous i.v. infusion of 2 mg.kg‐1 of morphine (group 3)
Number of subjects: 30
Study 1476277 — intervention group
Group type: COMPARATOR
Intervention: i.v. boluses of 2 mg of morphine (group 1)
Number of subjects: 30
Study 6144620 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrefazole 800 mg (4 capsules of 200 mg)
Number of subjects: 62
Study 6144620 — intervention group
Group type: COMPARATOR
Intervention: Placebo (4 capsules of identical appearance)
Number of subjects: 62
Study 30148432 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (cholecalciferol 100,000 IU)
Number of subjects: 59
Study 30148432 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 28482641 — intervention group
Group type: EXPERIMENTAL
Intervention: Bryostatin (25 μg/m2)
Number of subjects: 9